Interferon Alfa-2a [Recombinant] interactions
Checked as Interferon alfa-2a, Recombinant in this data source.
Full monograph for Interferon Alfa-2a [Recombinant]Check it against another medicine
Medicines
139 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Bupropion Hydrochloride | Major | Synergy | The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin… | 19 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Dextromethorphan + Bupropion | Major | Synergy | The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin… | 19 sources — open the full entry |
| Eltrombopag Olamine | Major | Others | In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse… | 6 sources — open the full entry |
| Iohexol | Major | Synergy | Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of… | 5 sources — open the full entry |
| Iopamidol | Major | Synergy | Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of… | 5 sources — open the full entry |
| Lamivudine + Zidovudine | Major | Synergy | The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or… | 16 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Major | Synergy | The coadministration of interferons and zidovudine (AZT) may result in severe bone marrow toxicity, most often manifested as granulocytopenia and/or… | 16 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 1 sources — open the full entry |
| Paracetamol + Tramadol Hydrochloride | Major | Synergy | The risk of seizures may be increased during coadministration of tramadol with any substance that can reduce the seizure threshold, such as selective serotonin… | 8 sources — open the full entry |
| Telbivudine | Major | Synergy | The risk and severity of peripheral neuropathy may be increased during coadministration of telbivudine with alfa interferons. The mechanism of interaction has… | 5 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Tramadol Hydrochloride | Major | Synergy | The risk of seizures may be increased during coadministration of tramadol with any substance that can reduce the seizure threshold, such as selective serotonin… | 8 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Adalimumab | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Aminophylline | Moderate | Metabolism | The coadministration with interferons has been associated with decreases in clearance and increases in plasma concentration and elimination half-life of… | 9 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Synergy | The concomitant use of recombinant interferon-alpha-2a and some angiotensin converting enzyme (ACE) inhibitors has been associated with a higher incidence of… | 4 sources — open the full entry |
| Asenapine Maleate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of asenapine, which is partially metabolized by the isoenzyme. | 5 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Bendamustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Bleomycin Sulfate | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or… | 4 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Capecitabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Captopril | Moderate | Synergy | The concomitant use of recombinant interferon-alpha-2a and some angiotensin converting enzyme (ACE) inhibitors has been associated with a higher incidence of… | 4 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carmustine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Chlorambucil | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 7 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Cisplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Colchicine | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Crizotinib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Dacarbazine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Dapsone | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Daunorubicin | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Decitabine | Moderate | Synergy | The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and… | 9 sources — open the full entry |
| Denosumab | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
Conditions
Conditions in which Interferon Alfa-2a [Recombinant] needs care, as documented in this source.
Autoimmune Diseases
MajorAntiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.
6 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories (2002):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Autoimmune Diseases
MajorAntiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis. Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.
6 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories (2002):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Central Nervous System Diseases
MajorReversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.
7 sources
- "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories (2002):
- "Product Information. Avonex (interferon beta-1a)." Biogen (2001):
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Central Nervous System Diseases
MajorReversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons. Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.
7 sources
- "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories (2002):
- "Product Information. Avonex (interferon beta-1a)." Biogen (2001):
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Depressive Disorder
MajorInterferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.
7 sources
- "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories (2002):
- "Product Information. Avonex (interferon beta-1a)." Biogen (2001):
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Depressive Disorder
MajorInterferons (alfa or beta) can induce depression and suicidal behavior. Suicidal attempts and suicides have been reported. Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression. Clinical monitoring of psychological status is recommended.
7 sources
- "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories (2002):
- "Product Information. Avonex (interferon beta-1a)." Biogen (2001):
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Heart Diseases
MajorHypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.
8 sources
- "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories (2002):
- "Product Information. Avonex (interferon beta-1a)." Biogen (2001):
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories (2002):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Heart Diseases
MajorHypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy. Therapy with interferons should be administered with caution in patients with compromised cardiac function.
8 sources
- "Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories (2002):
- "Product Information. Avonex (interferon beta-1a)." Biogen (2001):
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories (2002):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Hypothyroidism
MajorThyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.
5 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Hypothyroidism
MajorThyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons. Therapy with interferons should be administered cautiously to patients with thyroid dysfunction. If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued. Clinical monitoring of thyroid function is recommended.
5 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Kidney Diseases
MajorProteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).
6 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories (2002):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Kidney Diseases
MajorProteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy. Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported. Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction. Renal function should be evaluated in all patients before initiation of interferon- alfa therapy. In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance. A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).
6 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories (2002):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Liver Diseases
MajorDose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy. Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment. Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease. Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.
2 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
Liver Diseases
MajorDose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy. Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment. Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease. Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.
2 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
Bone Marrow Failure Disorders
ModerateInterferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.
5 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Bone Marrow Failure Disorders
ModerateInterferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression. Leukopenia is the primary manifestation. Thrombocytopenia and anemia occur less frequently. Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression. Clinical monitoring of hematopoietic function is recommended.
5 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
- "Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp (2021):
Diabetes Mellitus
ModerateFlu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.
4 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
Diabetes Mellitus
ModerateFlu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients. Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus. Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.
4 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
Peripheral Nervous System Diseases
ModerateParesthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.
4 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):
Peripheral Nervous System Diseases
ModerateParesthesia and numbness have been reported during interferon therapy. Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.
4 sources
- "Product Information. Intron A (interferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Infergen (interferon alfacon-1)." Amgen (2001):
- "Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation (2001):
- "Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation (2015):